Detection and Molecular Characterization of a Novel BRAF Activated Domain Mutation in Follicular Variant of Papillary Thyroid Carcinoma
Overview
Affiliations
To assess the mutational status of BRAF in FVPTC, we directly sequenced the genomic DNA of 30 primary FVPTC samples. BRAF mutations were found in only 4 (13%) tumors. We also identified a previously unknown (novel) mutation in the activation kinase domain of the BRAF (A598V), replacing alanine with valine. Functional analysis showed that this mutation led to the up-regulation of the BRAF kinase activity and its downstream signaling factors. The effect of this mutation on the structural formation of the protein is highlighted. Our results confirm the infrequency of BRAF (V600E) mutation in FVPTC and identify a novel (A598V) mutation of this gene.
von Ammon J, Machado G, da Matta R, Telles A, Carrijo F, Dos Santos B Arch Endocrinol Metab. 2024; 68:e240067.
PMID: 39420942 PMC: 11460960. DOI: 10.20945/2359-4292-2024-0067.
Unveiling a rare BRAF mutation in minimally invasive follicular thyroid carcinoma: A case report.
Lee P, Chen J, Pan L, Hwu C, Hang J, Kuo C Medicine (Baltimore). 2024; 103(34):e39364.
PMID: 39288226 PMC: 11346887. DOI: 10.1097/MD.0000000000039364.
Clinicopathologic Features of Diencephalic Neuronal and Glioneuronal Tumors.
Ho C, Bornhorst M, Almira-Suarez M, Donev K, Grafe M, Gordish-Dressman H J Neuropathol Exp Neurol. 2019; 79(1):67-73.
PMID: 31793986 PMC: 7850088. DOI: 10.1093/jnen/nlz115.
Dankner M, Rose A, Rajkumar S, Siegel P, Watson I Oncogene. 2018; 37(24):3183-3199.
PMID: 29540830 DOI: 10.1038/s41388-018-0171-x.
B-Raf mutation and papillary thyroid carcinoma patients.
Jiang L, Chu H, Zheng H Oncol Lett. 2016; 11(4):2699-2705.
PMID: 27073540 PMC: 4812206. DOI: 10.3892/ol.2016.4298.